RxDoctor Payments Data

Rozan Razzouk, MD

Family Medicine · South Miami, FLNPI 1245599596

Payments from drug & device makers

$1,744in general payments, 2019–2025

Across 57 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$673
  • AstraZeneca$463
  • Lexicon Pharmaceuticals, Inc.$122
  • Lilly USA, LLC$94
  • Kowa Pharmaceuticals America, Inc.$71
  • Exact Sciences$68
  • plus $253 from 10 others

What the payments were for

  • Food & beverage$1,73299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,744 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$35,738
Medicare patients
130
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide131$148,347
OzempicSemaglutide83$92,684
JardianceEmpagliflozin45$61,534
VascepaIcosapent Ethyl38$33,399
ProliaDenosumab14$22,610
FarxigaDapagliflozin Propanediol12$14,450
TrulicityDulaglutide11$14,446
EliquisApixaban12$13,169
Icosapent Ethyl24$10,433
SynthroidLevothyroxine Sodium29$3,235
Rosuvastatin Calcium180$2,601
Levothyroxine Sodium178$2,101
Atorvastatin Calcium191$1,645
Risedronate Sodium25$1,614
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$94$162,794142 claims
Novo NordiskOzempic$673$92,68483 claims
AstraZenecaFarxiga$463$14,45012 claims
AbbVieSynthroid$17$3,23529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →